Back to Top
research biosimilars
-
February 26, 2026
Apitegromab: A Myostatin Inhibitor for Spinal Muscular Atrophy
... -
February 25, 2026
Bentracimab: The First-in-Class Reversal Agent for Ticagrelor
... -
A Researcher’s Guide to Narsoplimab: Structure, Mechanism of Action, and Clinical Efficacy in TA-TMA
January 07, 2026Narsoplimab: Structure, Mechanism of Action, and Clinical Efficacy in TA-TMA
... -
December 22, 2025
Depemokimab: Structure, Mechanism of Action, and Clinical Efficacy in Eosinophilic Diseases
... -
December 03, 2025
Picankibart: Structure, Mechanism of Action, and Clinical Efficacy in Psoriasis
... -
A Researcher’s Guide to Sibeprenlimab: Structure, Mechanism of Action, and Clinical Efficacy in IgAN
November 30, 2025Sibeprenlimab: Structure, Mechanism of Action, and Clinical Efficacy in IgAN
... -
A Researcher’s Guide to Trastuzumab Botidotin: Structure, Mechanism of Action, and Clinical Efficacy
October 28, 2025Trastuzumab Botidotin: Structure, Mechanism of Action, and Clinical Efficacy
... -
-
February 01, 2024
Antibody therapeutics have made significant strides in recent years, with several successful treatments already in the market. However, the future of this field lies in the promising candidates currently in Phase I-II clinical trials. These antibodies, targeting a wide range of diseases, have the potential to become important treatments in the coming years.
One such antibody is DSP-0038, a humanized monoclonal antibody targeting the TROP2...
